Author
Listed:
- Mark J. Kiel
(University of Michigan Medical School)
- Anagh A. Sahasrabuddhe
(University of Michigan Medical School
Present address: Department of Biotechnology, Pandit Ravishankar Shukla University, Raipur, India.)
- Delphine C. M. Rolland
(Perelman School of Medicine at University of Pennsylvania)
- Thirunavukkarasu Velusamy
(University of Michigan Medical School)
- Fuzon Chung
(University of Michigan Medical School)
- Matthew Schaller
(University of Michigan Medical School)
- Nathanael G. Bailey
(University of Michigan Medical School)
- Bryan L. Betz
(University of Michigan Medical School)
- Roberto N. Miranda
(The University of Texas MD Anderson Cancer Center)
- Pierluigi Porcu
(The Ohio State University)
- John C. Byrd
(The Ohio State University)
- L. Jeffrey Medeiros
(The University of Texas MD Anderson Cancer Center)
- Steven L. Kunkel
(University of Michigan Medical School)
- David W. Bahler
(The University of Utah Health Sciences Center)
- Megan S. Lim
(Perelman School of Medicine at University of Pennsylvania)
- Kojo S. J. Elenitoba-Johnson
(Perelman School of Medicine at University of Pennsylvania
Center for Personalized Diagnostics, Perelman School of Medicine at University of Pennsylvania.)
Abstract
Sézary syndrome (SS) is an aggressive leukaemia of mature T cells with poor prognosis and limited options for targeted therapies. The comprehensive genetic alterations underlying the pathogenesis of SS are unknown. Here we integrate whole-genome sequencing (n=6), whole-exome sequencing (n=66) and array comparative genomic hybridization-based copy-number analysis (n=80) of primary SS samples. We identify previously unknown recurrent loss-of-function aberrations targeting members of the chromatin remodelling/histone modification and trithorax families, including ARID1A in which functional loss from nonsense and frameshift mutations and/or targeted deletions is observed in 40.3% of SS genomes. We also identify recurrent gain-of-function mutations targeting PLCG1 (9%) and JAK1, JAK3, STAT3 and STAT5B (JAK/STAT total ∼11%). Functional studies reveal sensitivity of JAK1-mutated primary SS cells to JAK inhibitor treatment. These results highlight the complex genomic landscape of SS and a role for inhibition of JAK/STAT pathways for the treatment of SS.
Suggested Citation
Mark J. Kiel & Anagh A. Sahasrabuddhe & Delphine C. M. Rolland & Thirunavukkarasu Velusamy & Fuzon Chung & Matthew Schaller & Nathanael G. Bailey & Bryan L. Betz & Roberto N. Miranda & Pierluigi Porcu, 2015.
"Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK–STAT pathway in Sézary syndrome,"
Nature Communications, Nature, vol. 6(1), pages 1-10, December.
Handle:
RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms9470
DOI: 10.1038/ncomms9470
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms9470. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.